• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
FinanceBayer

Bayer is going all in to create legal shields in Missouri, Iowa and Idaho against 170,000 Roundup weedkiller lawsuits it faces

By
David A. Lieb
David A. Lieb
and
The Associated Press
The Associated Press
Down Arrow Button Icon
By
David A. Lieb
David A. Lieb
and
The Associated Press
The Associated Press
Down Arrow Button Icon
May 22, 2024, 4:50 AM ET
Plastic containers Roundup
Maker of popular weedkiller Roundup amplifies fight against cancer-related lawsuits Geography Photos/Education Images/Universal Images Group via Getty Images

After failing in several U.S. states this year, global chemical manufacturer Bayer said Tuesday that it plans to amplify efforts to create a legal shield against a proliferation of lawsuits alleging it failed to warn that its popular weedkiller could cause cancer.

Bayer, which disputes the cancer claims, has been hit with about 170,000 lawsuits involving its Roundup weedkiller and has set aside $16 billion to settle cases. But the company contends the legal fight “is not sustainable” and is looking to state lawmakers for relief.

Bayer lobbied for legislation that could have blocked a central legal argument this year in Missouri, Iowa and Idaho — home, respectively, to its North America crop science division, a Roundup manufacturing facility and the mines from which its key ingredient is derived. Though bills passed at least one chamber in Iowa and Missouri, they ultimately failed in all three states.

But Bayer plans a renewed push during next year’s legislative sessions and may expand efforts elsewhere.

“This is bigger than just those states, and it’s bigger than just Bayer,” said Jess Christiansen, head of Bayer’s crop science and sustainability communications. “This is really about the crop protection tools that farmers need to secure production.”

Many U.S. farmers rely on Roundup, which was introduced 50 years ago as a more efficient way to control weeds and reduce tilling and soil erosion. For crops including corn, soybeans and cotton, it’s designed to work with genetically modified seeds that resist Roundup’s deadly effect.

The lawsuits allege Roundup’s key ingredient, glyphosate, causes a cancer called non-Hodgkin lymphoma. Though some studies associate glyphosate with cancer, the U.S. Environmental Protection Agency has said it is not likely to be carcinogenic to humans when used as directed.

The legislation backed by Bayer would protect pesticide companies from claims they failed to warn their products could cause cancer if their labels otherwise comply with EPA regulations.

Some lawmakers have raised concerns that if the lawsuits persist, Bayer could pull Roundup from the U.S. market, forcing famers to turn to alternatives from China.

Christiansen said Bayer has made no decisions about Roundup’s future but “will eventually have to do something different if we can’t get some consistency and some path forward around the litigation industry.”

Bayer’s most recent quarterly report shows that it shed more than 1,500 employees, reducing its worldwide employment to about 98,000. Bayer submitted a notice to Iowa that 28 people would be laid off starting Wednesday at its facility in Muscatine.

The Iowa layoffs are not a direct result of the failure of the protective legislation, Christiansen said, but are part of a global restructuring amid “multiple headwinds,” which include litigation.

Bayer has bankrolled a new coalition of agriculture groups that has run TV, radio, newspaper and billboard ads backing protective legislation for pesticide producers. The campaign has especially targeted Missouri, where most of the roughly 57,000 still active legal claims are pending. Missouri was the headquarters of Roundup’s original manufacturer, Monsanto, which Bayer acquired in 2018.

Legal experts say protective legislation is unlikely to affect existing lawsuits. But it could limit future claims.

The annual deadline to pass legislation in Missouri expired last Friday. Though a Bayer-backed bill cleared the Republican-led House and a Senate committee, it never got debated by the full GOP-led Senate, which was mired in unrelated tensions.

If the legislation is revived next year, it could face resistance from senators concerned about limiting people’s constitutional right to a jury trial to resolve disputes.

“I support farmers, but I also think they need due process,” said Republican state Sen. Jill Carter, who voted against the legislation this year in the Senate agriculture committee.

Fortune Brainstorm AI returns to San Francisco Dec. 8–9 to convene the smartest people we know—technologists, entrepreneurs, Fortune Global 500 executives, investors, policymakers, and the brilliant minds in between—to explore and interrogate the most pressing questions about AI at another pivotal moment. Register here.
About the Authors
By David A. Lieb
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon

Latest in Finance

Big TechOpenAI
OpenAI goes from stock market savior to burden as AI risks mount
By Ryan Vlastelica and BloombergDecember 7, 2025
36 minutes ago
InvestingStock
What bubble? Asset managers in risk-on mode stick with stocks
By Julien Ponthus, Natalia Kniazhevich, Abhishek Vishnoi and BloombergDecember 7, 2025
46 minutes ago
EconomyTariffs and trade
Macron warns EU may hit China with tariffs over trade surplus
By James Regan and BloombergDecember 7, 2025
56 minutes ago
EconomyTariffs and trade
U.S. trade chief says China has complied with terms of trade deals
By Hadriana Lowenkron and BloombergDecember 7, 2025
1 hour ago
PoliticsCongress
Leaders in Congress outperform rank-and-file lawmakers on stock trades by up to 47% a year, researchers say
By Jason MaDecember 7, 2025
1 hour ago
EconomyFederal Reserve
Jerome Powell faces a credibility issue as he tries to satisfy hawks and doves on the most divided Fed in recent memory
By Jason MaDecember 7, 2025
5 hours ago

Most Popular

placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
1 day ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
1 day ago
placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
1 day ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
2 days ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
1 day ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
11 days ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.